Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples